|
 
 
Thrombosis Research Section Faculty
Faculty (Secondary Appointment)
Research Interests:
Neal S. Kleiman, M.D. is an Associate Professor of Medicine, Cardiology
Section, Baylor College of Medicine, and Assistant Director of the
Cardiac Catheterization Laboratories, The Methodist DeBakey Heart
Center. Dr. Kleiman's research falls into two general areas. First,
he has collaborated on a large number of clinical trials in patients
with acute coronary syndromes undergoing percutaneous coronary intervention
(PCI), and has served on the steering committees of many of these
trials. The focus has been on design, recruitment, and compilation
of data in a large number of trials of thrombolytic agents, direct
thrombin antagonists, and antiplatelet agents. The second focus of
Dr. Kleiman's research is to elucidate the mechanisms responsible
for thrombotic complications of PCI. As a result, he has been involved
in the identification of patients at risk for vascular thrombosis
and has studied platelet aggregation responses in a number of clinical
settings and in pharmacologic dosing studies that he has initiated.
Selected Publications:
1. 1. Mazur W, Kaluza GL, Sapp S, Balog C, Topol EJ, Mark DB, Ellis
SG, Kereiakes DJ, Lincoff AM, Kleiman NS. Glycoprotein IIb-IIIa inhibition
with abciximab and postprocedural risk assessment: Lessons from the
evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication
for ad hoc use of glycoprotein IIb-IIIa antagonists. Am Heart J.
2002 Apr;143(4):594-601.
2. Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S,
Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao
T. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin
given in combination with glycoprotein IIb/IIIa antagonist eptifibatide.
Am Heart J. 2002 Apr;143(4):585-593.
3. Kleiman NS, Grazeiadei N, Maresh K, Taylor RJ, Frederick B, Lance
ET, Effron MB, Jordan RE, Mascelli MA: Abciximab, ticlopidine, and
concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation
inhibition profiles in patients undergoing percutaneous coronary interventions.
Am Heart J 2000 Sep;140(3):492-501.
4. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey
AA, Gibson CM, Guigliano RP, Mascelli AM, Scherer J, Barnathan ES,
Braunwald E, Kleiman NS: High levels of platelet inhibition with abciximab
despite heightened platelet activation and aggregation during thrombolysis
for acute myocardial infarction: Results from TIMI (Thrombolysis in
Myocardial Infarction) 14. Circulation 2000 Jun 13;101(23):2690-5.
5. Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman
HF, Jordan RE: Therapeutic heparin concentrations augment platelet
reactivity: Implications for the pharmacologic assessment of the glycoprotein
IIb/IIIa antagonist abciximab. Am Heart J 2000 Apr;139(4):
696-703.
6. Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan
LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EK, Califf
RM, Harrington RA: Early percutaneous coronary intervention, platelet
inhibition with eptifibatide, and clinical outcomes in patients with
acute coronary syndromes. Circulation 2000 Feb 22;101(7)751-7.
7. Kleiman NS, Tracy RP, Talley JD, Sigmon K, Joseph D, Topol EJ,
Califf RM, Kitt M, Ohman EM: Inhibition of platelet aggregation with
a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation
in patients undergoing thrombolysis for acute myocardial infarction.
J Thromb Thrombolysis 2000 Jan;9(1):5-12.
 ©1995-2003
Baylor College of Medicine
Email: medicine@bcm.tmc.edu
URL: http://public.bcm.tmc.edu/medicine/kleiman.htm (Modified: June 3, 2003)
|